218 related articles for article (PubMed ID: 19565568)
1. DNA methylation and histone modification regulate silencing of OPG during tumor progression.
Lu TY; Kao CF; Lin CT; Huang DY; Chiu CY; Huang YS; Wu HC
J Cell Biochem; 2009 Sep; 108(1):315-25. PubMed ID: 19565568
[TBL] [Abstract][Full Text] [Related]
2. Gene promoter methylation in prostate tumor-associated stromal cells.
Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
[TBL] [Abstract][Full Text] [Related]
3. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
5. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines.
Shao L; Cui Y; Li H; Liu Y; Zhao H; Wang Y; Zhang Y; Ng KM; Han W; Ma D; Tao Q
Clin Cancer Res; 2007 Oct; 13(19):5756-62. PubMed ID: 17908965
[TBL] [Abstract][Full Text] [Related]
6. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
7. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
Soejima H; Nakagawachi T; Zhao W; Higashimoto K; Urano T; Matsukura S; Kitajima Y; Takeuchi M; Nakayama M; Oshimura M; Miyazaki K; Joh K; Mukai T
Oncogene; 2004 May; 23(25):4380-8. PubMed ID: 15007390
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers.
Taniguchi H; Yamamoto H; Hirata T; Miyamoto N; Oki M; Nosho K; Adachi Y; Endo T; Imai K; Shinomura Y
Oncogene; 2005 Nov; 24(53):7946-52. PubMed ID: 16007117
[TBL] [Abstract][Full Text] [Related]
9. MT1G hypermethylation is associated with higher tumor stage in prostate cancer.
Henrique R; Jerónimo C; Hoque MO; Nomoto S; Carvalho AL; Costa VL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1274-8. PubMed ID: 15894685
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
11. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer.
Wang J; Thompson B; Ren C; Ittmann M; Kwabi-Addo B
Prostate; 2006 May; 66(6):613-24. PubMed ID: 16388505
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer is characterized by epigenetic silencing of 14-3-3sigma expression.
Lodygin D; Diebold J; Hermeking H
Oncogene; 2004 Dec; 23(56):9034-41. PubMed ID: 15489902
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
Collard RL; Harya NS; Monzon FA; Maier CE; O'Keefe DS
Prostate; 2006 May; 66(7):687-95. PubMed ID: 16425203
[TBL] [Abstract][Full Text] [Related]
14. IGSF4 promoter methylation and expression silencing in human cervical cancer.
Li J; Zhang Z; Bidder M; Funk MC; Nguyen L; Goodfellow PJ; Rader JS
Gynecol Oncol; 2005 Jan; 96(1):150-8. PubMed ID: 15589594
[TBL] [Abstract][Full Text] [Related]
15. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells.
Yamada N; Nishida Y; Tsutsumida H; Hamada T; Goto M; Higashi M; Nomoto M; Yonezawa S
Cancer Res; 2008 Apr; 68(8):2708-16. PubMed ID: 18413738
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells.
Zhang Z; Joh K; Yatsuki H; Zhao W; Soejima H; Higashimoto K; Noguchi M; Yokoyama M; Iwasaka T; Mukai T
Cancer Lett; 2007 Mar; 247(2):318-27. PubMed ID: 16806674
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
18. Functional epigenomics identifies genes frequently silenced in prostate cancer.
Lodygin D; Epanchintsev A; Menssen A; Diebold J; Hermeking H
Cancer Res; 2005 May; 65(10):4218-27. PubMed ID: 15899813
[TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of death-associated protein kinase gene in laryngeal squamous cell cancer.
Kong WJ; Zhang S; Guo C; Zhang S; Wang Y; Zhang D
Laryngoscope; 2005 Aug; 115(8):1395-401. PubMed ID: 16094112
[TBL] [Abstract][Full Text] [Related]
20. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.
Hinshelwood RA; Melki JR; Huschtscha LI; Paul C; Song JZ; Stirzaker C; Reddel RR; Clark SJ
Hum Mol Genet; 2009 Aug; 18(16):3098-109. PubMed ID: 19477956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
